Personalized cancer vaccine shows promise in early trial
NCT ID NCT03289962
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested a personalized cancer vaccine (RO7198457) in 273 patients with advanced solid tumors like melanoma, lung, and breast cancer. The vaccine was given alone or with an immunotherapy drug (atezolizumab) to see if it was safe and how the body responded. The goal was to find the best dose and check for side effects, not to cure the cancer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Akademiska sjukhuset, Onkologkliniken
Uppsala, 75185, Sweden
-
Antoni van Leeuwenhoek Ziekenhuis
Amsterdam, 1066 CX, Netherlands
-
Barts Health NHS Trust - St Bartholomew's Hospital
London, EC1M 6BQ, United Kingdom
-
CHU de Liège (Sart Tilman)
Liège, 4000, Belgium
-
Clinica Universitaria de Navarra
Pamplona, Navarre, 31008, Spain
-
Columbia University Medical Center
New York, New York, 10032, United States
-
Comprehensive Cancer Centers of Nevada (CCCN) - Central Valley
Las Vegas, Nevada, 89169, United States
-
Dana Farber Can Ins
Boston, Massachusetts, 02215, United States
-
Fachklinik für Lungenerkrankungen
Immenhausen, 34376, Germany
-
HonorHealth Research Institute ? Bisgrove
Scottsdale, Arizona, 85258, United States
-
Karolinska Universitetssjukhuset, Solna
Stockholm, 751 85, Sweden
-
Massachusetts General Hospital.
Boston, Massachusetts, 02114, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Nationales Centrum für Tumorerkrankungen Heidelberg (NCT)
Heidelberg, 69120, Germany
-
Princess Margaret Cancer Center
Toronto, Ontario, M5G 2M9, Canada
-
Providence Oncology and Hematology Care Eastside
Portland, Oregon, 97213, United States
-
Sarah Cannon Res Inst
Nashville, Tennessee, 37203, United States
-
Seattle Cancer Care Alliance
Seattle, Washington, 98109, United States
-
Southampton General Hospital
Southampton, SO16 6YD, United Kingdom
-
Stanford Cancer Center
Stanford, California, 94305, United States
-
The Los Angeles Clinic
Los Angeles, California, 90025, United States
-
The Ottawa Hospital Cancer Centre
Ottawa, Ontario, K1H 8L6, Canada
-
The Royal Marsden Hospital
Sutton, SM2 5PT, United Kingdom
-
UCSF Comprehensive Cancer Ctr
San Francisco, California, 94143, United States
-
UZ Gent
Ghent, 9000, Belgium
-
Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz
Mainz, 55101, Germany
-
Universitair Medisch Centrum Utrecht
Utrecht, 3584 CX, Netherlands
-
University of Colorado
Aurora, Colorado, 80045-2517, United States
-
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, 73104, United States
-
Universitätsklinikum Essen
Essen, 45122, Germany
-
Vall d?Hebron Institute of Oncology (VHIO), Barcelona
Barcelona, 08035, Spain
-
Yale University Cancer Center, Smilow Cancer Hospital
New Haven, Connecticut, 06511, United States
-
ZAS Sint Augustinus Wilrijk
Wilrijk, 2610, Belgium
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop colon polyps from coming back?
- A stitch in time: could a device make abdominal closure safer?
- Can we predict chemo brain before it happens?
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Your gut bacteria might reveal hidden cancer risk
- Can a Bag-Like device pull bladder tumors out whole?